Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, N6A5C1, Canada.
Department of Biology, Brandon University, Brandon, Manitoba, R7A6A9, Canada.
BMC Cancer. 2019 Jun 11;19(1):561. doi: 10.1186/s12885-019-5771-5.
Over-expression of cyclooxygenase (COX)-2 promotes breast cancer progression by multiple mechanisms, including induction of stem-like cells (SLC). Combined gene expression and microRNA microarray analyses of empty vector vs COX-2- transfected COX-2 low MCF7 breast cancer cell line identified two COX-2-upregulated microRNAs, miR-526b and miR-655, both found to be oncogenic and SLC-promoting. Cytoplasmic Polyadenylation Element-Binding Protein 2 (CPEB2) was the single common target of both microRNAs, the functions of which remain controversial. CPEB2 has multiple isoforms (A-F), and paradoxically, a high B/A ratio was reported to impart anoikis-resistance and metastatic phenotype in triple- negative breast cancer cells. We tested whether CPEB2 is a tumor suppressor in mammary epithelial cells.
We knocked-out CPEB2 in the non-tumorigenic mammary epithelial cell line MCF10A by CRISPR/Cas9-double nickase approach, and knocked-down CPEB2 with siRNAs in the poorly malignant MCF7 cell line, both lines being high CPEB2-expressing. The resultant phenotypes for oncogenity were tested in vitro for both lines and in vivo for CPEB2KO cells. Finally, CPEB2 expression was compared between human breast cancer and non-tumor breast tissues.
CPEB2 (isoform A) expression was inversely correlated with COX-2 or the above microRNAs in COX-2-divergent breast cancer cell lines. CPEB2KO MCF10A cells exhibited oncogenic properties including increased proliferation, migration, invasion, EMT (decreased E-Cadherin, increased Vimentin, N-Cadherin, SNAI1, and ZEB1) and SLC phenotype (increased tumorsphere formation and SLC marker-expression). Tumor-suppressor p53 protein was shown to be a novel translationally-regulated target of CPEB2, validated with polysome profiling. CPEB2KO, but not wild-type cells produced lung colonies upon intravenous injection and subcutaneous tumors and spontaneous lung metastases upon implantation at mammary sites in NOD/SCID/IL2Rϒ-null mice, identified with HLA immunostaining. Similarly, siRNA-mediated CPEB2 knockdown in MCF7 cells promoted oncogenic properties in vitro. Human breast cancer tissues (n = 105) revealed a lower mRNA expression for CPEB2 isoform A and also a lower A/B isoform ratio than in non-tumour breast tissues (n = 20), suggesting that CPEB2A accounts for the tumor-suppressor functions of CPEB2.
CPEB2, presumably the isoform A, plays a key role in suppressing tumorigenesis in mammary epithelial cells by repressing EMT, migration, invasion, proliferation and SLC phenotype, via multiple targets, including a newly-identified translational target p53.
环氧化酶(COX)-2 的过度表达通过多种机制促进乳腺癌的进展,包括诱导干细胞样细胞(SLC)。对空载体与 COX-2 转染的 COX-2 低 MCF7 乳腺癌细胞系的 COX-2 表达和 microRNA 微阵列进行联合基因表达和 microRNA 微阵列分析,鉴定出两种 COX-2 上调的 microRNA,miR-526b 和 miR-655,两者均被发现具有致癌性和促进 SLC 的作用。细胞质多聚腺苷酸化元件结合蛋白 2(CPEB2)是这两种 microRNA 的唯一共同靶标,其功能仍存在争议。CPEB2 有多个同工型(A-F),矛盾的是,据报道高 B/A 比值在三阴性乳腺癌细胞中赋予了抗凋亡和转移表型。我们测试了 CPEB2 是否在乳腺上皮细胞中是一种肿瘤抑制因子。
我们通过 CRISPR/Cas9-双切口方法在非致瘤性乳腺上皮细胞系 MCF10A 中敲除 CPEB2,并用 siRNA 在恶性程度较低的 MCF7 细胞系中敲低 CPEB2,这两种细胞系均高表达 CPEB2。对这两种细胞系的体外致癌表型和 CPEB2KO 细胞的体内表型进行了检测。最后,比较了人乳腺癌组织和非肿瘤乳腺组织中的 CPEB2 表达。
在 COX-2 不同的乳腺癌细胞系中,CPEB2(同工型 A)的表达与 COX-2 或上述 microRNA 呈负相关。CPEB2KO MCF10A 细胞表现出致癌特性,包括增殖、迁移、侵袭、上皮间质转化(E-Cadherin 减少,Vimentin、N-Cadherin、SNAI1 和 ZEB1 增加)和 SLC 表型(肿瘤球形成和 SLC 标志物表达增加)。研究表明,p53 蛋白是 CPEB2 的一种新的翻译调控靶标,这一发现通过多核糖体分析得到了验证。CPEB2KO 细胞而非野生型细胞在 NOD/SCID/IL2Rγ-/-小鼠静脉注射和皮下肿瘤以及植入乳腺部位后自发产生肺转移瘤,这通过 HLA 免疫染色得到了鉴定。同样,MCF7 细胞中 CPEB2 的 siRNA 介导敲低也促进了体外的致癌特性。105 例人乳腺癌组织(n=105)的 CPEB2 同工型 A 的 mRNA 表达水平以及 A/B 同工型比率均低于非肿瘤乳腺组织(n=20),这表明 CPEB2A 负责 CPEB2 的肿瘤抑制功能。
CPEB2,可能是同工型 A,通过多种靶标抑制 EMT、迁移、侵袭、增殖和 SLC 表型,包括新鉴定的翻译靶标 p53,从而在乳腺上皮细胞中发挥关键作用,抑制肿瘤发生。